Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
| Piqray | alpelisib | Advanced or Metastatic Breast Cancer | Do not reimburse | Complete | ||
| Perjeta | pertuzumab | Early stage breast cancer | Do not reimburse | Complete | ||
| MAR-Trientine | Trientine Hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete | ||
| Evenity | romosozumab | Osteoporosis, postmenopausal women | Reimburse with clinical criteria and/or conditions | Complete | ||
| Emgality | galcanezumab | Prevention of migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Esophageal or gastroesophageal junction cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tagrisso | osimertinib | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dojolvi | triheptanoin | Long-chain fatty acid oxidation disorders | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 11, 2024